Cost-effectiveness: will the public buy it or balk?
The prospect of cost-effectiveness as a criterion for treatment or coverage decisions may be met with stiff resistance from the public. A characteristically American reverence for new technology and abhorrence at putting a price on life conflict with the premise of value-based decisions. Nevertheless, if particular checks and balances are incorporated, consumer acceptance is possible. Since health care leaders deny that cost plays a role in coverage decisions, it may be time for a more realistic and open public debate on how to incorporate cost to achieve an optimal allocation of resources.